Turn Therapeutics Inc Financials
This page shows Turn Therapeutics Inc (TTRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Turn Therapeutics is in an externally financed balance-sheet build, with cash rising through financing while operations still absorb cash.
Cash reached$4.0M in FY2025 from$498K a year earlier. That improvement came while operating cash flow remained negative at-$2.6M and was enabled by$6.9M of financing inflows, so the higher cash balance reflects a funding event rather than self-funded operations.
The capital structure changed materially: equity moved from
The cost base is overwhelmingly SG&A-led: selling and administrative expense was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Turn Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Turn Therapeutics Inc carries a low D/E ratio of 1.59, meaning only $1.59 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 69/100, indicating a strong balance sheet with room for future borrowing.
Turn Therapeutics Inc's current ratio of 0.87 is below the typical benchmark, resulting in a score of 12/100. However, the company holds substantial cash reserves (67% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Turn Therapeutics Inc generates a -68.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Turn Therapeutics Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Turn Therapeutics Inc generates $0.80 in operating cash flow (-$2.6M OCF vs -$3.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Turn Therapeutics Inc's EBITDA was -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 231.8% from the prior year.
Turn Therapeutics Inc reported -$3.2M in net income in fiscal year 2025. This represents a decrease of 80.6% from the prior year.
Turn Therapeutics Inc earned $-0.12 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 71.4% from the prior year.
Cash & Balance Sheet
Turn Therapeutics Inc held $4.0M in cash against $0 in long-term debt as of fiscal year 2025.
Turn Therapeutics Inc had 29M shares outstanding in fiscal year 2025. This represents an increase of 9.7% from the prior year.
Margins & Returns
Turn Therapeutics Inc's ROE was -68.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Turn Therapeutics Inc invested $266K in research and development in fiscal year 2025. This represents an increase of 8.0% from the prior year.
TTRX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $109K | N/A | $159K+1614.0% | $9K | N/A | $153K |
| SG&A Expenses | $1.1M | N/A | $1.8M+367.0% | $376K | N/A | $520K |
| Operating Income | -$1.2M | N/A | -$1.9M-397.0% | -$385K | N/A | -$673K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$971K | N/A | -$1.9M-479.6% | -$329K | N/A | -$666K |
| EPS (Diluted) | $-0.03 | N/A | $-0.07-600.0% | $-0.01 | N/A | $-0.03 |
TTRX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|
| Total Assets | $18.6M+53.3% | $12.2M+183.0% | $4.3M | N/A | $2.0M | N/A |
| Current Assets | $11.5M+120.4% | $5.2M+57.7% | $3.3M | N/A | $1.1M | N/A |
| Cash & Equivalents | $11.0M+173.3% | $4.0M+684.1% | $514K-67.3% | $1.6M+215.6% | $498K0.0% | $498K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $12.5M+67.6% | $7.5M+97.1% | $3.8M | N/A | $2.2M | N/A |
| Current Liabilities | $5.1M-14.5% | $6.0M+160.0% | $2.3M | N/A | $708K | N/A |
| Long-Term Debt | $5.9M | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.1M+30.5% | $4.7M+829.9% | $504K-38.4% | $819K+561.4% | -$177K+57.2% | -$414K |
| Retained Earnings | -$23.4M-4.3% | -$22.4M+1.2% | -$22.7M | N/A | -$19.2M | N/A |
TTRX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.6M-38.8% | -$1.2M | N/A | -$298K+30.8% | -$431K | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$12K+61.1% | -$31K | N/A | N/A | -$8K | N/A |
| Financing Cash Flow | $7.8M+145.0% | $3.2M | N/A | $998K+91.1% | $522K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A |
TTRX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -15.9% | N/A | -377.8%-337.7pp | -40.1% | N/A | N/A |
| Return on Assets | -5.2% | N/A | -44.3% | N/A | N/A | N/A |
| Current Ratio | 2.23+1.4 | 0.87-0.6 | 1.43 | N/A | 1.55 | N/A |
| Debt-to-Equity | 0.97-0.6 | 1.59-5.9 | 7.53 | N/A | -12.55 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A |
Note: The current ratio is below 1.0 (0.87), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
Is Turn Therapeutics Inc profitable?
No, Turn Therapeutics Inc (TTRX) reported a net income of -$3.2M in fiscal year 2025.
What is Turn Therapeutics Inc's EBITDA?
Turn Therapeutics Inc (TTRX) had EBITDA of -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Turn Therapeutics Inc's return on equity (ROE)?
Turn Therapeutics Inc (TTRX) has a return on equity of -68.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Turn Therapeutics Inc's operating cash flow?
Turn Therapeutics Inc (TTRX) generated -$2.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Turn Therapeutics Inc's total assets?
Turn Therapeutics Inc (TTRX) had $12.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Turn Therapeutics Inc spend on research and development?
Turn Therapeutics Inc (TTRX) invested $266K in research and development during fiscal year 2025.
What is Turn Therapeutics Inc's current ratio?
Turn Therapeutics Inc (TTRX) had a current ratio of 0.87 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Turn Therapeutics Inc's debt-to-equity ratio?
Turn Therapeutics Inc (TTRX) had a debt-to-equity ratio of 1.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Turn Therapeutics Inc's return on assets (ROA)?
Turn Therapeutics Inc (TTRX) had a return on assets of -26.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Turn Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Turn Therapeutics Inc (TTRX) had $4.0M in cash against an annual operating cash burn of $2.6M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Turn Therapeutics Inc's Piotroski F-Score?
Turn Therapeutics Inc (TTRX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Turn Therapeutics Inc's earnings high quality?
Turn Therapeutics Inc (TTRX) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Turn Therapeutics Inc?
Turn Therapeutics Inc (TTRX) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.